Last reviewed · How we verify
Direct Sodium Removal Infusate 2.0
At a glance
| Generic name | Direct Sodium Removal Infusate 2.0 |
|---|---|
| Also known as | SGLT-2 inhibitor (dapagliflozin) |
| Sponsor | Sequana Medical N.V. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Direct Sodium Removal Infusate 2.0 CI brief — competitive landscape report
- Direct Sodium Removal Infusate 2.0 updates RSS · CI watch RSS
- Sequana Medical N.V. portfolio CI